Ca				-
1 2 3 4 5 6 7 8 9 10	Ali Razai (Bar No. 246922) ali.razai@knobbe.com Benjamin J. Everton (Bar No. 25 ben.everton@knobbe.com Christian Boettcher (Bar No. 342 christian.boettcher@knobbe.com <b>KNOBBE, MARTENS, OLSO</b> 2040 Main Street, Fourteenth Flo Irvine, CA 92614 Phone: (949) 760-0404 Facsimile: (949) 760-9502 Attorneys for Plaintiff <b>HYDRAFACIAL LLC</b> <b>IN THE UNITE</b>	950) <b>N &amp; BEAR, L</b> or		J <b>RT</b>
11	FOR THE CENTR	AL DISTRIC	T OF CALIFO	ORNIA
12	SOUTHERN DIVISION			
13				
14 15 16	HYDRAFACIAL LLC, formerly as EDGE SYSTEMS LLC, a Cal limited liability company,	ifornia 👌 CO		FOR PATENT
17	Plaintiff,	{	FRINGEMEN	
18	i iumini,	{ DI	EMAND FOR	JURY TRIAL
19	V.	ł		
20 21 22 23 24 25 26 27 28	EMIRAMED USA, LLC, a Delaware limited liability compa MIRAMEDTECH SP. Z.O.O., a limited liability company, and MIRAMEDTECH UG, a German limited liability company, Defendants.	Polish }		

Plaintiff HydraFacial LLC, formerly known as Edge Systems LLC
("HydraFacial" or "Plaintiff") hereby complains of Defendants eMIRAmed USA,
LLC ("eMIRAmed"), MIRAmedtech SP. Z.O.O. ("MIRAmedtech Poland") and
MIRAmedtech UG ("MIRAmedtech Germany") (collectively, "Defendants"),
and allege as follows:

6

### I. JURISDICTION AND VENUE

7
1. This is an action for patent infringement arising under the Patent
8
8
8
8
8
100, *et seq*.

9 2. As such, this is a civil action arising under the Constitution, laws, or
10 treaties of the United States and a civil action arising under any Act of Congress
11 relating to patents, and this Court has original subject matter jurisdiction over the
12 claims in this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

13 3. This Court has personal jurisdiction over Defendant eMIRAmed because eMIRAmed has a continuous, systematic, and substantial presence within 14 15 California and this judicial district. For example, eMIRAmed has a principal place 16 of business in this judicial district at 38 Tesla, Irvine, CA 92618. Plaintiff is 17 informed and believes, and thereon alleges, that eMIRAmed is also making, 18 using, selling, and or offering to sell infringing products in this judicial district 19 and/or sells such products into the stream of commerce knowing they will be sold in California and this judicial district. 20

21 4. This Court has personal jurisdiction over each of the Defendants 22 MIRAmedtech Poland and MIRAmedtech Germany because each of 23 MIRAmedtech Poland and MIRAmedtech Germany has a continuous, 24 systematic, and substantial presence within this judicial district. For example, 25 each of MIRAmedtech Poland and MIRAmedtech Germany has been importing, 26 selling and offering for sale infringing products in this district, and committing 27 acts of infringement in this district, including but not limited to, selling infringing 28 products to consumers and/or retailers in this district and selling into the stream

1 of commerce knowing such products would be sold in this district. These acts 2 form a substantial part of the events or omissions that give rise to Plaintiff's claim.

3

5. Alternatively, this Court may exercise jurisdiction over each of 4 Defendants MIRAmedtech Poland and MIRAmedtech Germany pursuant to 5 Federal Rule of Civil Procedure 4(k)(2) because Plaintiff's claim arises under federal law, each of Defendants MIRAmedtech Poland and MIRAmedtech 6 7 Germany would be a foreign defendant, and each of Defendants MIRAmedtech 8 Poland and MIRAmedtech Germany has sufficient contacts with the United 9 States as a whole, including, but not limited to, selling products, including the 10 infringing products, that are distributed throughout the United States, such that 11 this Court's exercise of jurisdiction over each of Defendants MIRAmedtech 12 Poland and MIRAmedtech Germany satisfies due process.

13

6. Venue is proper in this judicial district under 28 U.S.C. § 1400(b) as to Defendant eMIRAmed because Defendant eMIRAmed resides in this judicial 14 15 district, has a regular and established place of business located within this district, 16 and because Defendant eMIRAmed has committed acts of infringement by 17 offering to sell and/or selling infringing products in this judicial district.

18 7. Venue is proper in this judicial district under 28 U.S.C. §§ 1391 and 19 1400(b) as to each of Defendants MIRAmedtech Poland and MIRAmedtech Germany because each of Defendants MIRAmedtech Poland and MIRAmedtech 2021 Germany resides in this district by virtue of being an alien corporation and 22 because a substantial part of the events giving rise to Plaintiff's claim occurred in 23 this judicial district.

24

### **II. THE PARTIES**

-2-

Plaintiff is informed and believes and, based thereon, alleges that

25 8. Plaintiff HydraFacial is a California limited liability company having a principal place of business at 3600 E. Burnett Street, Long Beach, CA 26 27 90809. HydraFacial LLC recently changed its name from Edge Systems LLC.

28

9.

eMIRAmed USA, LLC is a Delaware limited liability company having its
 principal place of business located at 38 Tesla, Irvine, California 92618.

10. Plaintiff is informed and believes and, based thereon, alleges that
 MIRAmedtech SP. Z.O.O. is a Polish corporation having its principal place of
 business located at Powstańców Śląskich89A/235, 01-355 Warsaw, Poland.

6 11. Plaintiff is informed and believes and, based thereon, alleges that
7 MIRAmedtech UG is a German corporation having its principal place of business
8 located at Habichtweg 3-5, 75245 Neulingen, Baden-Württemberg, Germany.

#### 9

### III. <u>GENERAL ALLEGATIONS</u>

10

A.

### <u>The HydraFacial Patents and Technology</u>

11 12. HydraFacial is a worldwide leader in the design, development, manufacture, and sale of high-quality skin resurfacing and rejuvenation systems, 12 13 including hydrodermabrasion systems. These systems rejuvenate skin by 14 cleaning and exfoliating the skin surface, extracting debris from pores, and 15 nourishing the skin's surface with therapeutic solutions that moisturize and 16 protect the treated skin surface. HydraFacial markets and sells these systems 17 throughout the United States to, for example, dermatologists, plastic surgeons, 18 cosmetic physicians, and aestheticians at medical spas.

19 13. HydraFacial's latest flagship system is its revolutionary HydraFacial Syndeo® system, which is the premier hydrodermabrasion system sold in the 2021 United States. HydraFacial's revolutionary HydraFacial Syndeo® system is 22 protected by numerous United States patents, including U.S. Patent Nos. 23 9,550,052 (the "'052 Patent"), 11,446,477 (the "'477 Patent"), 11,865,287 (the "287 Patent"), and 12,053,607 (the "607 Patent") (collectively, the "Asserted 24 25 Patents"). In addition to the Syndeo® system, HydraFacial designs, develops, 26 manufactures and sells other patented hydrodermabrasion systems, including the 27 HydraFacial<sup>®</sup> Allegro<sup>™</sup> and the HydraFacial<sup>®</sup> Elite<sup>™</sup> systems. These 28 HydraFacial hydrodermabrasion systems are referred to herein collectively as

*I* "the HydraFacial® Systems."

14. On January 24, 2017, the USPTO duly and lawfully issued U.S.
Patent No. 9,550,052, titled "CONSOLE SYSTEM FOR THE TREATMENT OF
SKIN." A true and correct copy of the '052 Patent is attached hereto as Exhibit
1.

6 15. On September 20, 2022, the USPTO duly and lawfully issued U.S.
7 Patent No. 11,446,477, titled "DEVICES AND METHODS FOR TREATING
8 SKIN." A true and correct copy of the '477 Patent is attached hereto as Exhibit
9 2.

10 16. On January 9, 2024, the USPTO duly and lawfully issued U.S. Patent
11 No. 11,865,287, titled "DEVICES AND METHODS FOR TREATING SKIN."
12 A true and correct copy of the '287 Patent is attached hereto as Exhibit 3.

17. On August 6, 2024, the USPTO duly and lawfully issued U.S. Patent
14 No. 12,053,607, titled "DEVICES AND METHODS FOR TREATING SKIN."
15 A true and correct copy of the '607 Patent is attached hereto as Exhibit 4.

- 16 18. HydraFacial is the owner of all right, title, and interest in the
  17 Asserted Patents. HydraFacial therefore is the patentee for purposes of standing
  18 to assert the Asserted Patents in this action under 35 U.S.C. § 281.
- 19

# B. <u>Defendants' Infringing MIRApeel System</u>

20 19. Each of Defendants MIRAmedtech Poland and MIRAmedtech
21 Germany is in the business of sourcing, manufacturing, importing, promoting,
22 offering for sale, and selling aesthetic medical devices in the United States,
23 including hydrodermabrasion devices that compete with the HydraFacial®
24 Systems.

25 20. Defendant eMIRAmed is in the business of importing, promoting,
26 offering for sale, and selling aesthetic medical devices in the United States,
27 including hydrodermabrasion devices that compete with the HydraFacial®
28 Systems.

On information and belief, each of the Defendants markets and sells 1 21. 2 these medical devices throughout the United States to end users, such as 3 dermatologists, plastic surgeons, cosmetic physicians and aestheticians at medical spas. Each of the Defendants also offers replacement components, repairs, 4 5 warranties, and training services for end users.

One of the competing hydrodermabrasion devices used, sold, offered 6 22. 7 for sale, and/or imported into the United States by each of the Defendants is 8 known as the MIRApeel system, a skin treatment system that competes with the 9 HydraFacial® Systems. Each of the Defendants has sold and offered the 10 MIRApeel system for sale on their respective websites, and elsewhere online including social media platforms such as YouTube, Instagram, Facebook, and 11 12 LinkedIn. Defendants have also used brand representatives to advertise and sell 13 their products and services.

14 Defendant eMIRAmed's current website promoting the MIRApeel 23. 15 system is attached as **Exhibit 5**. Defendant MIRAmedtech Germany's current 16 website promoting the MIRApeel is attached as Exhibit 6. Defendant 17 eMIRAmed's website promoting the MIRAbrasor functionality of the MIRApeel 18 system is attached as **Exhibit 7**.

19 24. An example of a brochure distributed by Defendant MIRAmedtech Poland on Defendant MIRAmedtech Germany's website is attached hereto as 2021 **Exhibit 8**. Exhibit 8 is an example of one of the advertisements for the 22 MIRApeel system.

23 25. Defendants and their employees and affiliated spas have posted several instructive posts and videos on social media platforms. Excerpts from a 24 25 YouTube video from the account "MIRAmedtech" showing the MIRApeel system is use is attached as Exhibit 9. An Instagram post from the account 26 27 "mirapeel" showing the MIRApeel system is attached as Exhibit 10. An 28 Instagram post from the account "mirapeel" showing the MIRAbrasor handpiece

-5-

*i* is attached as Exhibit 11. Another Instagram post advertising the vacuum-aided
 *h*ydrodermabrasion functionality of the MIRAbrasor handpiece is attached as
 *Exhibit 12.*


26. The MIRApeel is a hydrodermabrasion device for treating the skin
surface of a patient. The MIRApeel system, shown in the images below, includes
a handpiece that is configured to receive a tip at the end of the handpiece. Exhibit
10. Defendants refer to this handpiece as the "MIRAbrasor" handpiece. Exhibit
7; see also Exhibit 5; Exhibit 6. Defendants also refer to the hydrodermabrasion
functionality of the MIRApeel as the "desquamating" or "dermal abrasion"
function. Exhibit 7.



# 21 **Exhibit 8**.

27. The MIRApeel system includes a manifold and a console that allows
a user to select the hydrodermabrasion functionalities, including controlling the
selection of solutions, flow of solutions, and vacuum suction. The MIRApeel
system also includes a vacuum source that creates suction for drawing the
patient's skin against the tip and removing material from the skin. Exhibits 6 and
9.

28



20 Exhibit 8; Exhibit 9.

21 28. The MIRApeel system delivers fluid from treatment material
22 containers to the skin. Defendants sell skin treatment materials. *See* Exhibit 8
23 (describing "MIRAjolie cosmetic serums"); *see also* Exhibit 9.

29. Defendant eMIRAmed also offers training and demonstrations on 24 25 the use of the MIRApeel system to end users and customers. In doing so, 26 Defendant eMIRAmed has used the MIRApeel system at least to demonstrate its operation, 27 evidenced by the videos cited above. See as https://emiramed.com/education (captured August 13, 2024) (Exhibit 13). 28

30. Defendants either had actual knowledge of the Asserted Patents (or
 their respective applications) when they began making, using, offering for sale
 and/or selling the infringing products, or they acted with willful blindness to their
 infringement.

- 5 31. Defendants were familiar with the industry when founding
  6 MIRAmedtech and eMIRAmed. <u>https://www.linkedin.com/in/serge4emiramed/</u>
  7 (captured August 13, 2024) (Exhibit 14) (showing experience of founder of each
  8 of Defendants). Each of the Defendants were competitors with Plaintiff in the
  9 skin resurfacing equipment industry when they first began selling the MIRApeel
  10 system.
- 32. Upon information and belief, each of the Defendants knew that
  Plaintiff was an industry leader at that time of Defendants' founding. Upon
  information and belief, each of the Defendants was familiar with Plaintiff and its
  aesthetic skin-resurfacing products when it launched the MIRApeel system.
- 15 Given this familiarity, Defendants necessarily would have 33. 16 researched Plaintiff and its patent portfolio before introducing the infringing 17 products. As part of that research, Defendants would have visited Plaintiff's 18 website, where at least the '052 Patent was prominently listed at least as early as 19 June 2018 (Exhibit 15), and where Plaintiff continues to list patents. See www.hydrafacial.com/patents/. Defendants additionally would have discovered 2021 the patents, and any published pending patents not listed through investigation. 22 See id. ("Additional patent applications pending").
- 34. At a minimum Defendants had actual knowledge of the Asserted
  Patents no later than August 6, 2024, when each of the Defendants received letters
  from Plaintiff informing each of the Defendants of the '477 Patent and '607 Patent
  and their infringement thereof. Copies of the letters are attached hereto as **Exhibits 16** and 17. Plaintiff later notified Defendants of their infringement of
  the remaining Asserted Patents on August 22, 2024. Exhibits 22 and 23.

*1* 35. Each of the Defendants have infringed and continue to infringe the *2* Asserted Patents.

3 36. Plaintiff has never authorized any of the Defendants to make, use,
4 offer for sale, import, or sell the MIRApeel System or other associated devices
5 that perform the accused functionalities.

6 37. Each of the Defendants' acts of infringement are and were willful,
7 intentional, and deliberate. Each of the Defendants has infringed and continues to
8 infringe each of the Asserted Patents with reckless disregard for Plaintiff's patent
9 rights. Defendants know, or should know, and knew, or should have known, that
10 their actions constituted and continue to constitute infringement of the Asserted
11 Patents.

### IV. <u>COUNT I</u>

12

13

### **INFRINGEMENT OF THE '052 PATENT**

*14* 38. HydraFacial incorporates by reference and realleges each of the *15* allegations set forth in Paragraphs 1-37 of this Complaint as if set forth fully *16* herein.


17 39. Each of the Defendants knowingly and intentionally infringed and 18 continue to infringe the '052 Patent under 35 U.S.C. § 271(a) through, for 19 example, the manufacture, use, sale, offer for sale, and/or importation into the 20United States of the MIRApeel system during the term of the '052 Patent. 21 Defendants MIRAmedtech Poland and MIRAmedtech Germany have 22 manufactured and imported into the United States the infringing MIRApeel 23 See https://www.linkedin.com/pulse/mira-announcement-devicesystem. 24 services-support-usa-miramedtech/ (captured July 1, 2024) (Exhibit 18) 25 ("MIRAmedtech UG, Germany, is the original inventors and the only FDA REGISTERED developer, designer, and manufacturer of aesthetic devices and 26 27 their associated proprietary MIRA accessories imported into the USA. These 28 devices include the MIRAx branded devices i.e., MIRApeel<sup>™</sup> MD, MIRAglam


1 (or MIRAslim) (sold by eMIRAmed USA)."); see also Exhibits 19 and 20 (FDA 2 registrations for MIRAmedtech Poland as manufacturer of MIRApeel system). 3 Defendant eMIRAmed has used, offered for sale, sold, and imported into the United States the infringing MIRApeel system. Exhibit 18 ("As a result, 4 eMIRAmed USA based in California has become our only exclusive US Importer 5 6 and Distributor of all MIRA branded devices and all our related proprietary accessories technology, as well as of all our next MIRAmedtech manufactured 7 8 devices and accessories.").


9 40. For example, as set forth in the claim chart below, the MIRApeel
10 system infringes at least Claim 1 of the '052 Patent.

system mininges at least chann 1 of the 052 f dent.		
'052 Patent	MIRApeel	
1. [pre] A	To the extent that the preamble is deemed to be a limitation, the	
system for	MIRApeel is a system for performing a skin treatment	
performing a skin treatment	procedure.	
procedure, the	The eMIRAmed website shows the MIRApeel:	
system	The civility lined website shows the funct speed.	
comprising:		
	MIRApeel	
	Exhibit 5 at 1; see also id. ("MIRApeel <sup>TM</sup> introduces the	
	Fractional Transbrasion <sup>TM</sup> revolution into a vast number of	
	skin-care modalities. It brings far-reaching new features,	
	aiming to make skin care procedures safer with better	
	control.").	
	-10-	


'052 Patent	MIRApeel
	The MIRAMedTech website states that the MIRApeel performs a treatment that "improves skin condition and so all skin problems visible after first treatment." <b>Exhibit 6</b>
	MIRAmedtech Poland provides a brochure which depicts MIRApeel:
	THE MIRAPEEL <sup>TM</sup> DEVICE Nourisher Deep Skin Brightening Molisturizer Complex Molisturizer Gentle
	Complex Restoring Exfolicitor
	Million and a second se
	MIRApeel <sup>ev</sup> : Comprehensive Cosmetic System designed to achieve novel 30 skin desquemation and Fractional Transbrasion <sup>ev</sup> MIRAPole <sup>ev</sup> : Non-invasive MIRAPole <sup>ev</sup> : Non-invasive Micro-Needling <sup>ev</sup> apparatus
	Exhibit 8 at 2. The brochure states that MIRApeel is a
	"Comprehensive Cosmetic System designed to achieve n
	3D skin desquamation and Fractional Transbrasion <sup>TM</sup> ." $I$
	The MIRAMedTech website includes a video that advert
	the MIRApeel system as a skin treatment system:
	and the
	Exhibit 0 at 1
	Exhibit 9 at 4.
[a] a console	The MIRApeel comprises a console including a manifold
including a	









1	'052 Patent	MIRApeel
2 3		brightening complex," respectively. <i>Id.</i> at 9–11. The first container and the at least second container contain different MIRAjolie treatment materials.
4 5 6		A video from the MIRAmedtech YouTube account displays the MIRAjolie serum bottles installed into the MIRApeel and labeled as "exfoliator," "detoxifier," and "moisturizer."
7 8		
9		
10 11		
11 12		
12		
14		
15		<b>Exhibit 9</b> at 2. Thus, the first container and the at least second
16 17		container are configured to contain treatment material for a skin treatment procedure, wherein the treatment material
18	[b] a handpiece	comprises a liquid. The MIRApeel comprises a handpiece assembly comprising a
19	assembly comprising a	tip, the tip being configured to contact a skin surface of a subject.
20	tip, the tip	
21	being configured to	The MIRAbrasor website describes the "MIRAbrasor <sup>TM</sup> attachment," which is "made of 2 parts" and is fixed to the end
22	contact a skin surface of a	of the handpiece assembly (the MIRAbrasor):
23 24	subject;	
24 25		
25 26		
27		
28		
		-15-








1052 D ( )	
'052 Patent	MIRApeel
[c] a supply	The MIRApeel comprises a supply conduit placing the manifold system in fluid communication with a handnices
conduit placing the manifold of	manifold system in fluid communication with a handpiece assembly, wherein the distal end of the supply conduit is
the console in	configured to couple to the handpiece assembly.
fluid	configured to couple to the nanopiece assentory.
communication	The MIRAMedTech website includes a photo of the MIRApeel
with the	system, showing the MIRApeel with a supply conduit
handpiece	connecting the console with the handpiece assembly:
assembly,	
wherein the distal end of	
the supply	Quality care at
conduit is	afforable rates Hencel Jackboker is the
configured to	MIRApeel Technology is the comprehensive skincare platform that provides professional results without
couple to the handpiece	the professional price tag.
assembly;	Conduit
ussemery,	
	Exhibit 6 at 6.
	The MIRAMedTech website describes "combin[ing] vacuum with infusion of active ingredients deep into the skin." <b>Exhibit</b>
	6 at 1. The MIRAbrasor website further describes a
	"MIRAbrasor" which performs skin abrasion "as the serums flow on the skin surface" through the MIRAbrasor. <b>Exhibit 7</b>
	at 2. Since the serum containers couple to the console via the
	manifold, the handpiece assembly is in fluid communication
	with the manifold to deliver serum through the handpiece
	assembly via a supply conduit.
	A post on the MIRApeel Instagram page shows the MIRApeel
	system with a supply conduit placing the manifold of the
	console in fluid communication with the handpiece assembly
	and having a distal end of the supply conduit configured to couple to the handpiece assembly.





	5
'052 Patent	MIRApeel
	Handpiece Supply Assembly
	Supply Assembly Conduit
	Exhibit 9 at 3.
	Exhibit 7 at 5.
[d] wherein the	
manifold is configured to	flow of treatment material from the first container and the at least second container through the supply conduit.
control a flow	
of treatment material from	As explained above, the manifold is in fluid communication with a first container and at least a second container. <i>See</i>
the first fluid	limitation 1[a], supra. As also explained above, the supply
container and at least the	conduit places the manifold system in fluid communication with the handpiece assembly. <i>See</i> limitation 1[b], <i>supra</i> . The
second fluid	first and the at least second container contain treatment
container through the	material. <i>See</i> limitation 1[a][i], <i>supra</i> . As shown below, the MIRApeel has at least one control to permit the flow from the
supply conduit;	
	conduit to the handpiece assembly.
	The eMIRAmed website shows the MIRApeel has "serum"
	knobs in communication with the manifold on the console:
	-20-















1	[h] wherein,	When the MIRApeel vacuum source is activated and the tip
2	when the	contacts the skin surface, a suction force is created within the
	vacuum source	waste conduit and along the tip, thereby removing waste from
3	is activated and	the skin surface via the waste conduit while drawing treatment
4	the tip contacts	material from the first fluid container or the second fluid
5	the skin surface, a	container to the tip via the supply conduit.
	suction force is	As explained above, the MIRApeel comprises (a) a vacuum
6	created within	source, (b) a handpiece assembly comprising a tip configured
7	the waste	to contact the skin surface of a subject, (c) a supply conduit
8	conduit and	placing the manifold in fluid communication with a handpiece
9	along the tip,	assembly, and (d) a waste conduit in fluid communication with
10	thereby removing	the handpiece assembly and the vacuum source to move waste away from the working end of the handpiece assembly during a
	waste from the	skin treatment procedure. See limitations 1[b], [c], [e], and [f],
11	skin surface	<i>supra</i> . As shown below, the vacuum source creates a suction
12	via the waste conduit while	force within the waste conduit and along the tip of the handpiece assembly to both help remove waste from the
13	drawing	handpiece assembly via the waste conduit and help transfer at
14	treatment	least one treatment material from the manifold system to the
15	material from the first fluid	handpiece assembly.
16	container or	The MIRAMedTech website describes "combin[ing] vacuum
	the second	with infusion of active ingredients deep into the skin."
17	fluid container	Exhibit 6 at 1.
18	to the tip via	
19	the supply conduit.	A post on the MIRApeel Instagram page describes how the MIRApeel uses "closed-loop technology: 2 tubes separating
20		the good from the bad."
20 21		
21		
23		
24		
25		
26		
27		
28		
		-27-



'052	atent MIRApeel
	Supply Conduit
	Handpiece
	Waste Conduit
	Conduit
	Exhibit 0 at 2. This fluid contains waste concreted during the
	<b>Exhibit 9</b> at 3. This fluid contains waste generated during the skin treatment procedure.
	As shown in the video, the user can turn on the vacuum source
	As shown in the video, the user can turn on the vacuum source and place the tip of the handpiece assembly against the skin,
	causing the MIRApeel to deliver treatment material from at least one of the at least two containers to the handpiece
	assembly via the supply conduit while removing waste from
	the skin surface via the waste conduit.
2	Each of the Defendants MIRAmedtech Poland, MIRAmedtech
	and eMIRAmed is liable under 35 U.S.C. § 271(b) for actively
	others to infringe the '052 Patent because, among other things, each of
	dants has marketed, sold, and offered for sale, and continues to market,
	offer for sale, the accused hydrodermabrasion products knowing and
	that such hydrodermabrasion products would be assembled or used by
	s and end users in a manner that infringes at least Claim 1 of the '052
Patent.	See Exhibits 5 and 6. For example, upon information and belief,
	ts eMIRAmed and MIRAmedtech Germany provided and provide
	ns and information to their customers and end users of the accused
	nabrasion products, encouraging assembly and use of the accused
-	nabrasion products in a manner that infringes the '052 Patent. See, e.g.,
•	<b>13</b> ; see also https://www.youtube.com/watch?v=FwKxhUfDFAI

-29-

(captured August 12, 2024) (Exhibit 21) (CEO of MIRAmedtech showing "Step-1 2 by-Step procedure" for performing MIRApeel treatment).

- 3 42. Further, customers and users have assembled and/or used the 4 accused hydrodermabrasion products in a manner that infringes the '052 Patent 5 (and continue to do so). See Exhibit 9 (showing an end user of the MIRApeel 6 system); Exhibit 21; see also Exhibit 13 (training webpage for MIRApeel).
- 7 Each of the Defendants MIRAmedtech Poland, MIRAmedtech 43. 8 Germany, and eMIRAmed is liable for contributory infringement under 35 U.S.C. 9 § 271(c) because, among other things, each of the Defendants has sold or offered 10 for sale, and continues to sell and/or offers for sale within the United States and/or 11 has imported and continues to import into the United States, the accused hydrodermabrasion products constituting material parts of the invention of at least 12 13 Claim 1 of the '052 Patent, that are not staple articles or commodities of 14 commerce suitable for substantial non-infringing use. See supra; Exhibits 5 and 15 6. Each of the Defendants has and continues to so act, knowing that the accused 16 hydrodermabrasion products are especially made for or adapted for use in an 17 infringement of the '052 Patent. See Exhibits 5-12. Further, customers and users 18 have assembled and/or used the accused hydrodermabrasion products in a manner 19 that infringes the '052 Patent (and continue to do so). See Exhibit 9 (showing an 20end user of the MIRApeel system); Exhibit 21; see also Exhibit 13 (training 21 webpage for MIRApeel).
- 22

As a direct and proximate result of Defendants' acts of infringement, 44. 23 each of the Defendants has derived and received gains, profits, and advantages. 24 Plaintiff has been damaged by each of the Defendants' activities, in an amount to 25 be determined at trial, but in no event less than a reasonable royalty.

26 45. Each of the Defendant's infringement has been and continues to be 27 Pursuant to 35 U.S.C. § 284, Plaintiff is entitled to damages for willful. 28 Defendants' infringing acts and treble damages together with interests and costs

as fixed by this Court.

- 46. This is an exceptional case. Pursuant to 35 U.S.C. § 285, Plaintiff is
  entitled to reasonable attorneys' fees for the necessity of bringing this action.
- 4 47. Due to the aforesaid infringing acts, Plaintiff has suffered irreparable
  5 injury, for which Plaintiff has no adequate remedy at law.

48. Unless enjoined by this Court, each of the Defendants will continue
to infringe Plaintiff's patent rights and cause Plaintiff further irreparable injury.

# 8 9

1

## V. <u>COUNT II</u>

## **INFRINGEMENT OF THE '477 PATENT**

49. HydraFacial incorporates by reference and realleges each of the
allegations set forth in Paragraphs 1-48 of this Complaint as if set forth fully
herein.

13 50. Each of the Defendants knowingly and intentionally infringed and continue to infringe the '477 Patent under 35 U.S.C. § 271(a) through, for 14 15 example, the manufacture, use, sale, offer for sale, and/or importation into the 16 United States of the MIRApeel system during the term of the '447 Patent. 17 MIRAmedtech Poland and MIRAmedtech Germany Defendants have 18 manufactured, sold and imported into the United States the infringing MIRApeel 19 system. See Exhibit 18 ("MIRAmedtech UG, Germany, is the original inventors 20and the only FDA REGISTERED developer, designer, and manufacturer of 21 aesthetic devices and their associated proprietary MIRA accessories imported into 22 the USA. These devices include the MIRAx branded devices i.e., MIRApeel<sup>TM</sup> 23 MD, MIRAglam (or MIRAslim) (sold by eMIRAmed USA)."); see also Exhibits 24 19 and 20 (FDA registrations for MIRAmedtech Poland as manufacturer of 25 MIRApeel system). Defendant eMIRAmed has used, offered for sale, sold, and 26 imported into the United States the infringing MIRApeel system. Exhibit 18 27 ("As a result, eMIRAmed USA based in California has become our only exclusive 28 US Importer and Distributor of all MIRA branded devices and all our related

*I* proprietary accessories technology, as well as of all our next MIRAmedtech *2* manufactured devices and accessories.").


3

4


51. For example, as set forth in the claim chart below, the MIRApeel system infringes at least Claim 1 of the '477 Patent.


5	'477 Patent	MIRApeel	
6	1. [pre] A	To the extent the preamble is deemed to be a limitation, the	
7	skin treatment	MIRApeel is a skin treatment system.	
8	system	The eMIRAmed website shows the MIRApeel:	
9	comprising:		
10			
11			
12			
13			
14		MRAppel	
15			
16			
17		<b>Exhibit 5</b> at 1; see also id. ("MIRApeel <sup>TM</sup> introduces the	
18		Fractional Transbrasion <sup>TM</sup> revolution into a vast number of skin-care modalities. It brings far-reaching new features,	
19		aiming to make skin care procedures safer with better	
20		control."). The MIRAMedTech website advertises that the MIRApeel	
21		performs a treatment that "improves skin condition and solves	
22		all skin problems visible after first treatment." <b>Exhibit 6</b> at 1.	
23		MIRAmedtech provides a brochure which depicts the	
24		MIRApeel:	
25			
26			
27			
28			
		-32-	








1	'477 Patent	MIRApeel
2 3 4		The MIRApeel video shows a system where the serum is emitted from the MIRApeel, through a handpiece assembly, directly onto the skin along the contact path. Therefore, the serum emitted from the MIRApeel handpiece assembly can be fluid from a first container and at least a second container.
5 6 7		Manifold System
8 9		(Internal) At least a second container
10 11		
12		
12		
14 15		
16		
17 18		
19		Exhibit 9 at 4.
20	[a][i] wherein	The MIRApeel has the first container and the at least second
21	each of the first container	container that are each configured to contain a treatment material.
22	and the at	
23	least second container is	As explained above, the MIRApeel comprises a manifold system in communication with a first container and at least a
24	configured	second container. See limitations 1[a], supra.
25	to contain a	The MID A need has a burn a description form the start we start 1
26	treatment material,	The MIRApeel brochure advertises four treatment materials ("MIRAjolie cosmetic products") for use with the MIRApeel
27		system:
28		























'477 Patent	MIRApeel
	<b>Exhibit 12</b> at 1.
	The MIP Areal video shows a knob on the MIP Areal used
	The MIRApeel video shows a knob on the MIRApeel used control the vacuum source.
	Display
	Vacuum Knob
	VACUUM FLO
	<b>Exhibit 9</b> at 3. As shown above, the MIRApeel displays the
	power of the vacuum when selected to the "Hydra" setting
[e] a wasta	The MIRApeel comprises a waste conduit in fluid
[e] a waste conduit in	communication with the handpiece assembly and the vacu
fluid	source to move waste away from the working end of the
communicati on with the	handpiece assembly during a skin treatment procedure.
handpiece	A post on the MIRApeel Instagram page describes how the
assembly and	MIRApeel uses "closed-loop technology: 2 tubes [i.e., a
the vacuum	supply conduit and a waste conduit] separating the good [i
source to move waste	serums through the supply conduit] from the bad [i.e., was suctioned away from the skin through the waste conduit]."
away from	
the working	
end of the handpiece	
assembly	
during a skin	
treatment procedure;	
and	
	-44-



1	'477 Patent	MIRApeel
2 3 4		
5 6 7 8		
9 10		<i>Id.</i> at 4.
11	[f] at least	The MIRApeel comprises at least one control to permit
12	one control to permit	control of a flow of treatment material from the first container and the at least second container through the supply conduit to
13	control of a	the handpiece assembly.
14	flow of treatment	As explained above, the manifold system is in fluid
15	material from	communication with a first container and at least a second
16	the first container and	container. <i>See</i> limitation 1[a], <i>supra</i> . As also explained above, the supply conduit places the manifold system in fluid
17	the at least	communication with the handpiece assembly. See limitation
18	second container	1[b], <i>supra</i> . The first and the at least second container contain treatment material. <i>See</i> limitation 1[a][i], <i>supra</i> . As shown
10 19	through the	below, the MIRApeel has at least one control to permit the
20	supply	flow from the first and the at least second container through
20	conduit to the handpiece	the supply conduit to the handpiece assembly.
	assembly;	The eMIRAmed website shows the MIRApeel has a "flow"
22		knob on the console:
23		
24		
25		
26		
27		
28		
		-46-



1	'477 Patent	MIRApeel
2		Flow
3		UDRK TIME 22:22 Rate Display
4		LD type Was Green Coppy Dimplet Tree
5		
		Flow Knob
6		
7		VACUUM FLO
8		Exhibit 0 at 2 As shown above the MID Apoel shows the
9		<b>Exhibit 9</b> at 3. As shown above, the MIRApeel shows the flow rate of the treatment material from the selected container
10		through the supply conduit to the handpiece assembly.
11	[a] whorein	The MIR A neel comprises a vacuum source configured to
12	[g] wherein the vacuum	The MIRApeel comprises a vacuum source configured to create a suction force within the waste conduit and along the
13	source is	working end of the handpiece assembly to help remove waste
	configured to	from the hand piece assembly via the waste conduit and to
14	create a suction force	help transfer at least one treatment material from the manifold
15	within the	system to the handpiece assembly.
16	waste conduit	As explained above, the MIRApeel comprises (a) a vacuum
17	and along the	source, (b) a handpiece assembly comprising a working end
18	working end of the	configured to contact the skin surface of a subject, (c) a supply conduit placing the manifold system in fluid
	handpiece	communication with a handpiece assembly, and (d) a waste
19	assembly to	conduit in fluid communication with the handpiece assembly
20	help remove waste from	and the vacuum source to move waste away from the working end of the handpiece assembly during a skin treatment
21	the hand	procedure. <i>See</i> limitations 1[b], [b][i], [d], and [e], <i>supra</i> . As
22	piece	shown below, the vacuum source creates a suction force
23	assembly via	within the waste conduit and along the working end of the
24	the waste conduit and	handpiece assembly to both help remove waste from the handpiece assembly via the waste conduit and help transfer at
	to help	least one treatment material from the manifold system to the
25	transfer at	handpiece assembly.
26	least one	
27	treatment	The MIRAMedTech website describes "combin[ing] vacuum
	material from	with infusion of active ingredients deep into the skin."
28	the manifold	Exhibit 6 at 1.



1	'477 Patent	MIRApeel	
2 3		The MIRApeel video shows what happens when the vacuum source is activated, and the working end of the handpiece assembly contacts the skin surface:	
4 5		Supply Conduit	
6 7		Waste Conduit Handpiece Assembly	
8 9			
10 11		<b>Exhibit 9</b> at 3. This fluid contains waste generated during the skin treatment procedure.	
12			
13		As shown in the video, the user can turn on the vacuum source and place the working end of the handpiece assembly against	
14		the skin, causing the MIRApeel to deliver at least one	
15 16		treatment material from at least one of the at least two containers to the handpiece assembly via the supply conduit.	
17			
18	52. Eac	ch of the Defendants MIRAmedtech Poland, MIRAmedtech	
19	Germany, and	eMIRAmed is liable under 35 U.S.C. § 271(b) for actively	
20	inducing others	to infringe the '477 Patent because, among other things, each of	
21	the Defendants	the Defendants has marketed, sold, and offered for sale, and continues to market,	
22	sell, and offer t	sell, and offer for sale, the accused hydrodermabrasion products knowing and	
23	intending that s	intending that such hydrodermabrasion products would be assembled or used by	
24	customers and end users in a manner that infringes at least Claim 1 of the '477		
25	Patent. See E	xhibits 5 and 6. For example, upon information and belief,	
26	Defendants eMIRAmed and MIRAmedtech Germany provided and provide		
27	instructions and information to their customers and end users of the accused		
28	hydrodermabras	sion products, encouraging assembly and use of the accused	

hydrodermabrasion products in a manner that infringes the '477 Patent. See, e.g., Exhibit 13; see also Exhibit 21 (CEO of MIRAmedtech showing "Step-by-Step procedure" for performing MIRApeel treatment).

3 4

5

6

7

1

2

Further, customers and users have assembled and/or used the 53. accused hydrodermabrasion products in a manner that infringes the '477 Patent (and continue to do so). See Exhibit 9 (showing an end user of the MIRApeel system); Exhibit 21; see also Exhibit 13 (training webpage for MIRApeel).

8 54. Each of the Defendants MIRAmedtech Poland, MIRAmedtech 9 Germany, and eMIRAmed is liable for contributory infringement under 35 U.S.C. 10  $\S$  271(c) because, among other things, each of the Defendants has sold or offered 11 for sale, and continues to sell and/or offers for sale within the United States and/or 12 has imported and continues to import into the United States, the accused 13 hydrodermabrasion products constituting material parts of the invention of at least 14 Claim 1 of the '477 Patent, that are not staple articles or commodities of 15 commerce suitable for substantial non-infringing use. See supra; Exhibits 5 and 16 6. Each of the Defendants has and continues to so act, knowing that the accused 17 hydrodermabrasion products are especially made for or adapted for use in an 18 infringement of the '477 Patent. See Exhibits 5–12. Further, customers and users 19 have assembled and/or used the accused hydrodermabrasion products in a manner 20that infringes the '477 Patent (and continue to do so). See Exhibit 9 (showing an 21 end user of the MIRApeel system); Exhibit 21; see also Exhibit 13 (training 22 webpage for MIRApeel).

23

55. As a direct and proximate result of Defendants' acts of infringement, 24 each of the Defendants has derived and received gains, profits, and advantages. 25 Plaintiff has been damaged by each of the Defendants' activities, in an amount to be determined at trial, but in no event less than a reasonable royalty. 26

27 56. Each of the Defendant's infringement has been and continues to be 28 Pursuant to 35 U.S.C. § 284, Plaintiff is entitled to damages for willful.

*I* Defendants' infringing acts and treble damages together with interests and costs *2* as fixed by this Court.

*3* 57. This is an exceptional case. Pursuant to 35 U.S.C. § 285, Plaintiff is *4* entitled to reasonable attorneys' fees for the necessity of bringing this action.

5 58. Due to the aforesaid infringing acts, Plaintiff has suffered irreparable
6 injury, for which Plaintiff has no adequate remedy at law.

59. Unless enjoined by this Court, each of the Defendants will continue
to infringe Plaintiff's patent rights and cause Plaintiff further irreparable injury.

### VI. COUNT III

### 10

9

# **INFRINGEMENT OF THE '287 PATENT**


60. HydraFacial incorporates by reference and realleges each of the
allegations set forth in Paragraphs 1-59 of this Complaint as if set forth fully
herein.


Each of the Defendants knowingly and intentionally infringed and 14 61. 15 continue to infringe the '287 Patent under 35 U.S.C. § 271(a) through, for 16 example, the manufacture, use, sale, offer for sale, and/or importation into the 17 United States of the MIRApeel system during the term of the '287 Patent. 18 Defendant MIRAmedtech Poland and/or MIRAmedtech Germany has 19 manufactured and imported into the United States the infringing MIRApeel 20system. See Exhibit 18 ("MIRAmedtech UG, Germany, is the original inventors" 21 and the only FDA REGISTERED developer, designer, and manufacturer of 22 aesthetic devices and their associated proprietary MIRA accessories imported into 23 the USA. These devices include the MIRAx branded devices i.e., MIRApeel<sup>™</sup> 24 MD, MIRAglam (or MIRAslim) (sold by eMIRAmed USA)."); see also Exhibits 25 19 and 20 (FDA registrations for MIRAmedtech Poland as manufacturer of 26 MIRApeel system). Defendant eMIRAmed has used, offered for sale, sold, and 27 imported into the United States the infringing MIRApeel system. Exhibit 18 28 ("As a result, eMIRAmed USA based in California has become our only exclusive


US Importer and Distributor of all MIRA branded devices and all our related
proprietary accessories technology, as well as of all our next MIRAmedtech
manufactured devices and accessories.").


62. For example, as set forth in the claim chart below, the MIRApeel
system infringes at least Claim 26 of the '287 Patent.


6	'287 Patent	MIRApeel
7	26. [pre] A	To the extent that the preamble is deemed to be a limitation,
8	system for treating skin,	the MIRApeel is a system for treating skin.
9	the system	The eMIRAmed website shows the MIRApeel:
10	comprising:	
10		
11 12		
13		VACUUM FLOW
14		
15		MRApeel
16		
17		
18		<b>Exhibit 5</b> at 1; see also id. ("MIRApeel <sup>TM</sup> introduces the
19		Fractional Transbrasion <sup>TM</sup> revolution into a vast number of skin-care modalities. It brings far-reaching new features,
20		aiming to make skin care procedures safer with better
21		control.").
22		The MIRAMedTech website advertises that the MIRApeel
23		performs a treatment that "improves skin condition and solves
24		all skin problems visible after first treatment." Exhibit 6 at 1.
25		The MIRApeel brochure depicts the MIRApeel:
26		
27		
28		
20		52
		-53-















1207 D 4 4	
'287 Patent	MIRApeel
	Exhibit 0 at 1
[c][ii]	<b>Exhibit 9</b> at 4. The block of the MIRApeel is configured to selectively
configured to	receive fluid from the at least one additional container when
selectively	the at least one additional container is connected to the
receive fluid	console. See limitation 1[c][i], supra.
from the at	
least one	
additional	
container when	
the at least one	
additional	
container is	
connected to	
the console;	
and [c][iii]	The block of the MIRApeel is configured to selectively be in
configured to	fluid communication with the handpiece through a first
selectively be	conduit when the handpiece is connected to the console.
in fluid	
communication	The eMIRAmed website provides a photo of the MIRApeel
with the	system in use, showing the MIRApeel with a handpiece:
handpiece	
through a first	
conduit when	
the handpiece	
is connected to	
the console;	
and	








'287 Patent	MIRApeel
	Exhibit 10 at 1.
	The MIRApeel video shows the serum bottles coupled to the
	console via the block such that, when the handpiece is placed
	against the skin, the MIRApeel draws fluid from the block to the handpiece via the first conduit:
	Console - Block (international console - Conso
	Serum Bottles
	Handpiece
	First Conduit
	Conduct
	Exhibit 9 at 3.
	Exhibit 9 at 5.
[d] a vacuum	The MIRApeel comprises a vacuum source.
source;	The eMIRAmed website indicates that the MIRApeel has a
	vacuum source, as the MIRApeel has a "vacuum" knob on the
	console:
	-62-
	-02-











[g] wherein 1 when the 2 handpiece is 3 connected to the console and 4 the first 5 container, the second 6 container and 7 the third container each 8 contains a fluid 9 and is connected to 10 the console, 11 the system is configured to 12 deliver to the 13 handpiece one at a time fluid 14 contained in 15 the first container. fluid 16 contained in 17 the second container, and 18 fluid contained 19 in the third container. 2021 22 23 24 25 26 27 28

When the handpiece is connected to the console, the first<br/>container, the second container and the third container each<br/>contains a fluid and is connected to the console, the<br/>MIRApeel system is configured to deliver to the handpiece<br/>one at a time fluid contained in the first container, fluid<br/>contained in the second container, and fluid contained in the<br/>third container.

Both the eMIRAmed website and MIRAMedTech website show a MIRApeel system that includes controls that deliver one at a time the treatment fluid from the first container, the second container, and the third container when the handpiece is connected to the console and the first container, the second container and the third container each contains a fluid and is connected to the console.

Controls



Exhibit 5 at 1; see also Exhibit 6 at 1 (same).

Similarly, the MIRApeel video shows the MIRApeel system in use. During use of the MIRApeel system, the video shows the handpiece connected to the console and the first container, the second container and the third container each containing a fluid and connected to the console.

1	'287 Patent	MIRApeel
2		
3		
4		
5		
6		
7		
8		
9		<b>Exhibit 9</b> at 2. Another video also demonstrates that the MIRApeel is
10		configured deliver to the handpiece one at a time fluid
11		contained in the first container, fluid contained in the second container, and fluid contained in the third container. <i>See</i>
12		Exhibit 21 at 1:55 (adjusting "Serum 1" knob from "Close"
13		to "Open"); <i>id.</i> at 2:09–3:48 (performing treatment).
14		
15	63. Each	n of the Defendants MIRAmedtech Poland, MIRAmedtech
16	Germany, and e	MIRAmed is liable under 35 U.S.C. § 271(b) for actively
17	inducing others to infringe the '287 Patent because, among other things, each of	
18	the Defendants ha	as marketed, sold, and offered for sale, and continues to market,
19	sell, and offer fo	r sale, the accused hydrodermabrasion products knowing and
20	intending that suc	ch hydrodermabrasion products would be assembled or used by
21	customers and en	nd users in a manner that infringes at least Claim 1 of the '287
22	Patent. See Ex	hibits 5 and 6. For example, upon information and belief,
23	Defendants eMI	RAmed and MIRAmedtech Germany provided and provide
24	instructions and	information to their customers and end users of the accused
25	hydrodermabrasi	on products, encouraging assembly and use of the accused
26	hydrodermabrasi	on products in a manner that infringes the '287 Patent. See
27	Exhibit 13; see a	lso Exhibit 21 (CEO of MIRAmedtech showing "Step-by-Step
28	procedure" for pe	erforming MIRApeel treatment).

1 64. Further, customers and users have assembled and/or used the 2 accused hydrodermabrasion products in a manner that infringes the '287 Patent 3 (and continue to do so). See Exhibit 9 (showing an end user of the MIRApeel system); Exhibit 21; see also Exhibit 13 (training webpage for MIRApeel). 4

5 65. Each of the Defendants is liable for contributory infringement under 35 U.S.C. § 271(c) because, among other things, each of the Defendants has sold 6 7 or offered for sale, and continues to sell and/or offers for sale within the United 8 States and/or has imported and continues to import into the United States, the 9 accused hydrodermabrasion products constituting material parts of the invention 10 of at least Claim 1 of the '287 Patent, that are not staple articles or commodities 11 of commerce suitable for substantial non-infringing use. See supra; Exhibits 5 12 and 6. Each of the Defendants has and continues to so act, knowing that the 13 accused hydrodermabrasion products are especially made for or adapted for use 14 in an infringement of the '287 Patent. See Exhibits 5-12. Further, customers and 15 users have assembled and/or used the accused hydrodermabrasion products in a 16 manner that infringes the '287 Patent (and continue to do so). See Exhibit 9 17 (showing an end user of the MIRApeel system); Exhibit 21; see also Exhibit 13 18 (training webpage for MIRApeel).

19 66. As a direct and proximate result of Defendants' acts of infringement, each of the Defendants has derived and received gains, profits, and advantages. 2021 Plaintiff has been damaged by each of the Defendants' activities, in an amount to 22 be determined at trial, but in no event less than a reasonable royalty.

23

67. Each of the Defendant's infringement has been and continues to be 24 willful. Pursuant to 35 U.S.C. § 284, Plaintiff is entitled to damages for 25 Defendants' infringing acts and treble damages together with interests and costs as fixed by this Court. 26

27 68. This is an exceptional case. Pursuant to 35 U.S.C. § 285, Plaintiff is 28 entitled to reasonable attorneys' fees for the necessity of bringing this action.

5

6

- *I* 69. Due to the aforesaid infringing acts, Plaintiff has suffered irreparable *injury*, for which Plaintiff has no adequate remedy at law.
- 3 70. Unless enjoined by this Court, each of the Defendants will continue
  4 to infringe Plaintiff's patent rights and cause Plaintiff further irreparable injury.

### VII. COUNT IV


# **INFRINGEMENT OF THE '607 PATENT**


7 71. HydraFacial incorporates by reference and realleges each of the
8 allegations set forth in Paragraphs 1-70 of this Complaint as if set forth fully
9 herein.


10 72. Each of the Defendants MIRAmedtech Poland, MIRAmedtech 11 Germany, and eMIRAmed knowingly and intentionally infringed and continue to 12 infringe the '607 Patent under 35 U.S.C. § 271(a) through, for example, the 13 manufacture, use, sale, offer for sale, and/or importation into the United States of 14 the MIRApeel system during the term of the '607 Patent. Defendant 15 MIRAmedtech Poland and/or MIRAmedtech Germany has manufactured and 16 imported into the United States the infringing MIRApeel system. See Exhibit 18 17 ("MIRAmedtech UG, Germany, is the original inventors and the only FDA 18 REGISTERED developer, designer, and manufacturer of aesthetic devices and 19 their associated proprietary MIRA accessories imported into the USA. These 20devices include the MIRAx branded devices i.e., MIRApeel<sup>™</sup> MD, MIRAglam 21 (or MIRAslim) (sold by eMIRAmed USA)."); see also Exhibits 19 and 20 (FDA 22 registrations for MIRAmedtech Poland as manufacturer of MIRApeel system). 23 Defendant eMIRAmed has used, offered for sale, sold, and imported into the 24 United States the infringing MIRApeel system. Exhibit 18 ("As a result, 25 eMIRAmed USA based in California has become our only exclusive US Importer 26 and Distributor of all MIRA branded devices and all our related proprietary 27 accessories technology, as well as of all our next MIRAmedtech manufactured 28 devices and accessories.").


*1*73. For example, as set forth in the claim chart below, the MIRApeel *2*system infringes at least Claim 1 of the '607 Patent.


3		MID Areal
3	Claim 1 1. [pre] A	MIRApeel To the extent that the preamble is deemed to be a limitation, the
4	skin	MIRApeel is a skin treatment system.
5	treatment	
6	system, comprising:	The eMIRAmed website shows the MIRApeel:
7		
8		
9		
10		
11		VACUUM FLOW
12 13		MIRApeel
14 15		
		Exhibit 5 at 1; see also id. ("MIRApeel <sup>TM</sup> introduces the
16		Fractional Transbrasion <sup>TM</sup> revolution into a vast number of skin-
17		care modalities. It brings far-reaching new features, aiming to
18		make skin care procedures safer with better control.").
19		The MIRAMedTech website advertises that the MIRApeel
20		performs a treatment that "improves skin condition and solves all skin problems visible after first treatment." <b>Exhibit 6</b> at 1.
21		
22		MIRAmedtech provides a brochure which depicts the MIRApeel:
23		
24		
25		
26		
27		
28		
		-72-






























Claim 1	MIRApeel
[d] a vacuum source configured to create a vacuum that draws waste material from the handpiece through the waste line	The MIRApeel has a vacuum source configured to create a vacuum that draws waste material from the handpiece through the waste line for disposal. The eMIRAmed website indicates that the MIRApeel has a vacuum source, as the MIRApeel has a "vacuum" knob on the console:
for disposal	Console – Vacuum Knob
	Exhibit 5 at 1; see also Exhibit 6 at 1. The MIRAMedTech website, under its "How MIRA works" section, states that "[u]nlike traditional treatments, [the MIRA treatment] is performed with a device that combines <i>vacuum</i> with infusion of active ingredients deep into the skin." Exhibit 6 at 1 (emphasis added).
	A MIRApeel Instagram post shows the MIRAbrasor handpiece and describes the treatment as "utilizing a groundbreaking <i>vacuum-aided</i> hydrodermabrasion and microchanneling process" as well as "adjustable suction and serum for better extractions."
	-83-









hydrodermabrasion products in a manner that infringes the '607 Patent. See, e.g., Exhibit 13; see also Exhibit 21 (CEO of MIRAmedtech showing "Step-by-Step procedure" for performing MIRApeel treatment).

3 4

5

6

7

1

2

Further, customers and users have assembled and/or used the 75. accused hydrodermabrasion products in a manner that infringes the '607 Patent (and continue to do so). See Exhibit 9 (showing an end user of the MIRApeel system); Exhibit 21; see also Exhibit 13 (training webpage for MIRApeel).

8 76. Each of the Defendants MIRAmedtech Poland, MIRAmedtech 9 Germany, and eMIRAmed is liable for contributory infringement under 35 U.S.C. 10  $\S$  271(c) because, among other things, each of the Defendants has sold or offered 11 for sale, and continues to sell and/or offers for sale within the United States and/or 12 has imported and continues to import into the United States, the accused 13 hydrodermabrasion products constituting material parts of the invention of at least 14 Claim 1 of the '607 Patent, that are not staple articles or commodities of 15 commerce suitable for substantial non-infringing use. See supra; Exhibits 5 and 16 6. Each of the Defendants has and continues to so act, knowing that the accused 17 hydrodermabrasion products are especially made for or adapted for use in an 18 infringement of the '607 Patent. See Exhibits 5-12. Further, customers and users 19 have assembled and/or used the accused hydrodermabrasion products in a manner 20that infringes the '607 Patent (and continue to do so). See Exhibit 9 (showing an 21 end user of the MIRApeel system); Exhibit 21; see also Exhibit 13 (training 22 webpage for MIRApeel).

23

77. As a direct and proximate result of Defendants' acts of infringement, 24 each of the Defendants has derived and received gains, profits, and advantages. 25 Plaintiff has been damaged by each of the Defendants' activities, in an amount to be determined at trial, but in no event less than a reasonable royalty. 26

27 78. Each of the Defendant's infringement has been and continues to be 28 Pursuant to 35 U.S.C. § 284, Plaintiff is entitled to damages for willful.

*I* Defendants' infringing acts and treble damages together with interests and costs *2* as fixed by this Court.

*79.* This is an exceptional case. Pursuant to 35 U.S.C. § 285, Plaintiff is *entitled to reasonable attorneys' fees for the necessity of bringing this action.*

5 80. Due to the aforesaid infringing acts, Plaintiff has suffered irreparable
6 injury, for which Plaintiff has no adequate remedy at law.

81. Unless enjoined by this Court, each of the Defendants will continue
to infringe Plaintiff's patent rights and cause Plaintiff further irreparable injury.

9

## VIII. <u>PRAYER FOR RELIEF</u>

WHEREFORE, Plaintiff HydraFacial prays for judgment in its favor and
 against Defendants for the following relief:

A. A judgment in favor of Plaintiff and against each of the Defendants
on all claims alleged herein;

B. A judgment that each of the Defendants has infringed and continue
to infringe the '052 Patent, '477 Patent,'287 Patent, and '607 Patent under 35
U.S.C. § 271;

C. A preliminary and permanent injunction enjoining each of the
Defendants, their officers, directors, agents, servants, employees, and attorneys,
and those persons in active concert or participation with each of the Defendants,
from (1) making, using, selling, offering to sell, and/or importing into the United
States the MIRApeel system or inducing others to use them in an infringing
manner, and (2) infringing the Asserted Patents in violation of 35 U.S.C. § 271;

D. An accounting of all of each of the Defendant's gains, profits, and
advantages derived from each of their infringement of the Asserted Patents in
violation of 35 U.S.C. § 271;

E. An Order that each of the Defendants pays to Plaintiff actual
damages in the form of lost profits, or, in the alternative, other damages adequate
to compensate for the infringement, but in no event less than a reasonable royalty

1	for the use made of the patented inventions by each of the Defendants, in		
2	accordance with 35 U.S.C. § 284;		
3	F. An Order finding that Defendant's infringement has been willful and		
4	trebling or otherwise increasing damages pursuant to 35 U.S.C. § 284 because of		
5	each of the Defendants' willful infringement;		
6	G. An Order finding this case exceptional under 35 U.S.C. § 285 and		
7	ordering each of the Defendants to pay Plaintiff its reasonable attorneys' fees		
8	incurred in this action;		
9	H. An award of pre-judgment and post-judgment interest and costs as		
10	fixed by the Court; and		
11	I. Such other and further relief as this Court may deem just and proper.		
12			
13	IX. <u>DEMAND FOR JURY TRIAL</u>		
14	Plaintiff HydraFacial LLC hereby demands a trial by jury of all issues so		
15	triable.		
16 17	Respectfully submitted,		
17			
18 10	KNOBBE, MARTENS, OLSON & BEAR, LLP		
19 20	Dated: August 26, 2024 By: /s/ Ali S. Razai		
20 21	Ali S. Razai		
22	Benjamin J. Everton Christian D. Boettcher		
22	Attorneys for Plaintiff Hydrafacial LLC		
24			
25			
26			
27			
28			
	-90-		